If you had bought Laboratorios Farmaceuticos Rovi on 11 November 2025, the last twelve months might now look very different in your portfolio. For Laboratorios Farmaceuticos Rovi shareholders, the return over the past year was 21.2%, including dividends. At the start, investors were staring at falling CDMO sales and profit pressure on heparin, yet also hearing bullish plans for injectables capacity and Okedi. If you were weighing those cross-currents then, which side of that trade-off would have felt more convincing?
A Narrative on Simply Wall St is one investor's written case for a company, with its growth, margin and multiple assumptions spelled out. Those assumptions imply an estimated Fair Value.
If the move has made Laboratorios Farmaceuticos Rovi harder to judge, start where the gap is still open and scan 196 high quality undervalued stocks.
The Two Stories Investors Were Choosing Between On Laboratorios Farmaceuticos Rovi
The shares cost €59.15 at the start of the period, and investors in Laboratorios Farmaceuticos Rovi had to decide which story about the business felt more realistic.
On the optimistic side sat a Fair Value of €78.95 that leaned on specialty pharma momentum and heavier CDMO investment. This case depended on Okedi and other injectables filling expanded European capacity and turning higher volumes into better profitability.
The cautious view pointed to a Fair Value of €51.25 and treated the future as cloudy. It rested on slower 4.0% revenue growth, 18.0% profit margins, and concern that weak CDMO demand and a delayed US rollout could weigh on results for years.
What The Results Changed For Laboratorios Farmaceuticos Rovi
The biggest new fact was that Laboratorios Farmaceuticos Rovi reported Q3 2026 revenue of €266.01m and net income of €78.416m, with net margin rising to 29.5%. That improvement backed parts of the optimistic profitability story. At the same time, lower 2026 revenue guidance to low to mid single digit growth, tied to softer pharma demand and a revised CDMO contract, supported the cautious view. Overall, the evidence cut both ways.
The key assumption here was how resilient CDMO and injectables demand would be. For a different stock with a similar pitch, track reported contract manufacturing revenue, margin trends and any changes to growth guidance against what management outlined around your decision date.
What Laboratorios Farmaceuticos Rovi's Price Now Asks You To Believe
Laboratorios Farmaceuticos Rovi now trades at €70.7, and the analyst consensus Narrative on Simply Wall St sees its Fair Value as higher than that market quote.
The Narrative leans on specialty injectables, Okedi and CDMO scale to carry heavier R&D and heparin pressure, so you would be judging whether sustained CDMO contract visibility really holds.
"A key requirement for the strategy to work is that Rovi converts heavy R&D and capex spending into successful ISM-based products and efficient heparin vertical integration so that rising costs and lower heparin prices do not erode the current gross margin profile."
The price and this Narrative do not agree. → Uncover what this Narrative says Laboratorios Farmaceuticos Rovi is actually worth
Go Straight To The Source
The story behind this run has already been told. The next one could be taking shape somewhere else. Where could you start looking before it becomes the headline?
- Company 1 - 15% below our estimate - targets contractors that are only now adopting tiltrotators at larger project scales.
- Company 2 - 28% below our estimate - builds a single digital hub where advisers and direct investors coordinate portfolios.
- Company 3 - 34% below our estimate - links AI software spending directly to expanding cloud infrastructure and data center deployments.
Those are three of them. See the full list of 193 financially solid companies →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com